<DOC>
	<DOCNO>NCT00573157</DOCNO>
	<brief_summary>The purpose study learn whether atacicept treatment lead improvement kidney function subject active lupus nephritis combination mycophenolate mofetil ( MMF ) corticosteroid . The study sponsor Merck Serono International ; operational oversight provide ZymoGenetics .</brief_summary>
	<brief_title>The Efficacy Safety Atacicept Combination With Mycophenolate Mofetil Used Treat Lupus Nephritis</brief_title>
	<detailed_description />
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Diagnosis systemic lupus erythematosus ( SLE ) satisfy least 4 11 American College Rheumatology ( ACR ) criterion ( Appendix B ) Renal biopsy perform consistent active International Society Nephrology/Renal Pathology Society ( ISN/PRS ) class III IV lupus nephritis Estimated glomerular filtration rate ( GFR ) less equal ( &lt; = ) 30 milliliter per minute ( mL/min ) per 1.73 square meter ( m^2 ) Active central nervous system SLE deem severe progressive and/or associate significant cognitive impairment Any treatment MMF , azathioprine , cyclophosphamide within last 6 month , know hypersensitivity MMF atacicept . Any prior treatment abatacept , rituximab , belimumab , B cell modulate agent .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>nephritis</keyword>
	<keyword>atacicept</keyword>
</DOC>